Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Camel milk as an adjuvant therapy for the treatment of type 1 diabetes: verification of a traditional ethnomedical practice.

Mohamad RH, Zekry ZK, Al-Mehdar HA, Salama O, El-Shaieb SE, El-Basmy AA, Al-said MG, Sharawy SM.

J Med Food. 2009 Apr;12(2):461-5. doi: 10.1089/jmf.2008.0009.

PMID:
19459752
2.

Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial.

Agrawal RP, Jain S, Shah S, Chopra A, Agarwal V.

Eur J Clin Nutr. 2011 Sep;65(9):1048-52. doi: 10.1038/ejcn.2011.98. Epub 2011 Jun 1.

PMID:
21629270
3.

Camel milk as an adjunct to insulin therapy improves long-term glycemic control and reduction in doses of insulin in patients with type-1 diabetes A 1 year randomized controlled trial.

Agrawal RP, Beniwal R, Kochar DK, Tuteja FC, Ghorui SK, Sahani MS, Sharma S.

Diabetes Res Clin Pract. 2005 May;68(2):176-7. Epub 2005 Feb 24. No abstract available.

PMID:
15860247
4.

Beneficial effect of camel milk in diabetic nephropathy.

Agrawal RP, Dogra R, Mohta N, Tiwari R, Singhal S, Sultania S.

Acta Biomed. 2009 Aug;80(2):131-4.

PMID:
19848050
5.

Effect of camel milk on glucose metabolism in adults with normal glucose tolerance and type 2 diabetes in Raica community: a crossover study.

Agrawal RP, Sharma P, Gafoorunissa SJ, Ibrahim SA, Shah B, Shukla DK, Kaur T.

Acta Biomed. 2011 Dec;82(3):181-6.

PMID:
22783713
6.

Camel milk: a possible boon for type 1 diabetic patients.

Agrawal RP, Tantia P, Jain S, Agrawal R, Agrawal V.

Cell Mol Biol (Noisy-le-grand). 2013 Nov 3;59(1):99-107. Review.

PMID:
24200025
7.

Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

Diabetes. 2001 Aug;50(8):1778-84.

8.

A study of the anti-diabetic agents of camel milk.

Malik A, Al-Senaidy A, Skrzypczak-Jankun E, Jankun J.

Int J Mol Med. 2012 Sep;30(3):585-92. doi: 10.3892/ijmm.2012.1051. Epub 2012 Jun 29.

PMID:
22751901
11.
13.

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.

PMID:
11783602
14.

Glycaemic control of insulin-dependent diabetes mellitus in Sudan: influence of insulin shortage.

Elbagir MN, Eltom MA, Rosling H, Berne C.

Diabetes Res Clin Pract. 1995 Oct;30(1):43-52.

PMID:
8745205
15.

[The role of insulin secretion and insulin resistance in the clinical course of newly diagnosed diabetes mellitus in children].

Szadkowska A, Pietrzak I, Markuszewski L, Bodalski J.

Med Wieku Rozwoj. 2005 Apr-Jun;9(2):223-34. Polish.

PMID:
16085963
16.
17.

Serum leptin concentrations in children with type 1 diabetes mellitus: relationship to body mass index, insulin dose, and glycemic control.

Soliman AT, Omar M, Assem HM, Nasr IS, Rizk MM, El Matary W, El Alaily RK.

Metabolism. 2002 Mar;51(3):292-6.

PMID:
11887162
18.

Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.

Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A.

Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19.

PMID:
23512415
19.

Impaired beta-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes.

Elder DA, Woo JG, D'Alessio DA.

Pediatr Diabetes. 2010 Aug;11(5):314-21. doi: 10.1111/j.1399-5448.2009.00601.x.

20.

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

Coron Artery Dis. 2001 Aug;12(5):413-23.

PMID:
11491207

Supplemental Content

Support Center